Syros is redefining the power of small molecules to control the expression of genes with the aim of providing a profound benefit for patients. We are advancing a pipeline of gene control medicines for cancer and monogenic diseases.

Latest Annual Report

For Year Ending December 31, 2021

View Annual Report

Stock Information

Syros Pharmaceuticals, Inc.


Nasdaq: SYRS




52 week Low/High

Day Low/High

Company Overview

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including tamibarotene (formerly SY-1425), a first-in-class oral selective RARĪ± agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia, and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Latest Presentation


Our people are our backbone. Touting years of experience in a variety of fields, our leadership team is the source of our success.

IR Contact Information

Investor Relations

Syros Pharmaceuticals
Karen Hunady
Director of Corporate Communications & Investor Relations

Stern Investor Relations, Inc.
Hannah Deresiewicz

Transfer Agent

Computershare Trust Company, N.A.